


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours
per response: 4.0

1 lequer's Identity			
1. Issuer's Identity CIK (Filer ID Number)	Previous Name(s)	▼ None	Entity Type
	Trevious (vanic(s)	1 Tronc	
0001800802			© Corporation
Name of Issuer			C Limited Partnership
Iterum Therapeutics Bermuda	Ltd		C Limited Liability Company
Jurisdiction of Incorporation/Organization			C General Partnership
BERMUDA			C Business Trust
Year of Incorporation/Organ	ization		C
O Over Five Years Ago			Other
Within Last Five Years	2019		
(Specify Year) O Yet to Be Formed			
ice to be I office			
2. Principal Place of	of Business and	Contact In	formation
Name of Issuer			
Iterum Therapeutics Bermuda	Ltd		
Street Address 1		Street Address 2	
CLARENDON HOUSE		2 CHURCH ST	TREET
	State/Province/Country		
City	State/Province/Country		
HAMILTON	BERMUDA	HM 11	312-778-6070
1. Issuer's Identity CIK (Filer ID Number)	Previous Name(s)	None	Entity Type
0001659323	Iterum Therapeu	tics Ltd	6 -
Name of Issuer			Corporation
Iterum Therapeutics plc			Limited Partnership
Jurisdiction of			C Limited Liability Company
Incorporation/Organization			C General Partnership
IRELAND			C Business Trust
Year of Incorporation/Organ	ization		C Other
Over Five Years Ago			Other
e Within Last Five Years (Specify Year)	2015		
C Yet to Be Formed			
2. Principal Place of	of Business and	Contact In	formation
Name of Issuer			
Iterum Therapeutics plc			
Street Address 1		Street Address 2	
	NIDT CENTRE		
BLOCK 2 FLOOR 3, HARCO		HARCOURT	
City	State/Province/Country	y ZIP/Postal	Code Phone No. of Issuer
DUBLIN	IRELAND		(872) 225-6077




IRELAND				C B	usiness Trust
Year of Incorporation/	Organization	1		_	
Over Five Years Ago				C Ot	her
 Within Last Five Year (Specify Year) 	20 20	15			
C Yet to Be Formed					
O. Duin aire al Dia	f D.		O = t = - t t		·
2. Principal Pla	ice of Bu	isiness and	Contact Int	orma	tion
Iterum Therapeutics I	nternational	Ltd			
Street Address 1	nter national	Liu	Street Address 2		
BLOCK 2 FLOOR 3 H	ARCOURT	ENTRE	HARCOURT S	STREET	1
City		te/Province/Country			Phone No. of Issuer
DUBLIN		RELAND			353-1-903-8920
DOBLIN		CLAND			333-1-703-0720
3. Related Pers	sons				
	301.0				
Last Name		First Name		Middle	Name
Fishman		Corey		N.	
Street Address 1			Street Address 2		
Block 2 Floor 3, Harc	ourt Centre		Harcourt Street		
City		State/Province/Cou	ntry	ZIP/Pos	tal Code
Dublin		IRELAND		2	
Relationship:	Executi	ive Officer	Director		Promoter
Clarification of Response	(if Necessary)			
		<u>′</u>			
Last Name		First Name		Middle	Name
Matthews		Judith		M.	
Street Address 1			Street Address 2		
Block 2 Floor 3, Hard	ourt Centre		Harcourt Street		
City		State/Province/Cou	ntry	ZIP/Pos	tal Code
Dublin		IRELAND		2	
Relationship:	Executi	ive Officer	Director		Promoter
	D-0000				
Clarification of Response	(if Necessary)			

F

-1

Last Name	First Name		Middle Name	
Hunt	Ronald		M.	
Street Address 1		Street Address 2	2	
Block 2 Floor 3, Ha	rcourt Centre	Harcourt Stre	eet	
City	State/Provi	nce/Country	ZIP/Postal Code	
Dublin	IRELANI		2	
Relationship:	Executive Officer	▽ Director	Promoter	
		(Proceed)	W	
Clarification of Respon	se (if Necessary)			
Last Name	First Name		Middle Name	
Malik	Shahzad			
Street Address 1		Street Address 2		
Block 2 Floor 3, Ha	rcourt Centre	Harcourt Stre	eet	
City		nce/Country	ZIP/Postal Code	
Dublin	IRELANI	0	2	
	To see		las ser	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Respon	se (if Necessary)			
Last Name	First Name		Middle Name	
Kelly	David			
Street Address 1		Street Address 2	<u></u> 1 2	
Block 2 Floor 3, Ha	rcourt Centre	Harcourt Stre		
City		nce/Country	ZIP/Postal Code	
Dublin	IRELANI		2	
Relationship:	Executive Officer	▽ Director	Promoter	
Relationship:	Executive Officer	Director	Fromoter	
Clarification of Respon	se (if Necessary)			
Last Name	First Name		Middle Name	
Matthews	Judith		M.	
Street Address 1		Street Address 2	2	
Clarendon House		2 Church Stre	eet	
City	State/Provi	nce/Country	ZIP/Postal Code	
Hamilton	BERMUI)A	HM 11	
Relationship:	Executive Officer	▽ Director	Promoter	
		F8000	*	
Clarification of Respon	se (if Necessary)			
Last Name	First Name		Middle Name	



	Federal Exemption(oly)	s) and Exclusion(s) Claimed (select all that
app	Rule 504(b)(1) (not (i), (ii)	
	or (iii))	Rule 505
	Rule 504 (b)(1)(i)	▼ Rule 506(b)
	Rule 504 (b)(1)(ii)	
1	Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
		Investment Company Act Section 3(c)
7	Type of Filing	
7	New Notice Date of First Sa	ale 2020-01-21 First Sale Yet to Occur
	Amendment	
3. Ī	Duration of Offering	
oes	the Issuer intend this offering to	last more than one year?
)	Type(s) of Securities	s Offered (select all that apply)
	Pooled Investment Fund Interests	Equity
		▼ Debt
1	Mineral Property Securities	Option, Warrant or Other Right to
	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Acquire Another Security Other (describe)
	Business Combina	00.00
	action, such as a merger, acquisit	
lari	fication of Response (if Necessary	2)
	Minimum Investme	
Iinii ivesi	mum investment accepted from a tor	ny outside \$ 0 USD
	Calaa Camananati	on
2.	Sales Compensation	
	sales Compensation	Recipient CRD Number None
Recij	·	Recipient CRD Number None None
Reci _j SV	B Leerink LLC	39011 (Associated) Broker or Dealer CRD None
SV.	pient	39011
SV Asso	B Leerink LLC	39011 (Associated) Broker or Dealer CRD None
SV Asso	B Leerink LLC ciated) Broker or Dealer	None (Associated) Broker or Dealer CRD None Number
SV Asso	B Leerink LLC ociated) Broker or Dealer et Address 1	39011 ✓ None

Total Offering Amount \$ 51588000 □ Indefinite
Total Amount Sold \$ 51588000 USD
Total Remaining to be \$ 0 USD ☐ Indefinite
Clarification of Response (if Necessary)
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
Regardless of whether securities in the offering have been or may be sold
to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finders' Fees Expenses
Describe consentative the consents of rates consentrations and find and for a second of the consent of the
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$ 1391400 USD Estimate
Finders' Fees \$ 0 USD Estimate
Finders Fees 3
Clarification of Response (if Necessary)
40.11 (D
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to
any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$ 0 USD Estimate
5 USD Estimate
Clarification of Response (if Necessary)
Signature and Submission
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. Terms of Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. Terms of Submission
before signing and clicking SUBMIT below to file this notice. Terms of Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. Terms of Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. Terms of Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. Terms of Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. Terms of Submission

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

I also am a duly authorized representative of the other identified issuer(s) in Item 1 above and authorized to sign on their behalf.

Issuer	Signature	Name of Signer	Title	Date
Iterum Therapeutics Bermuda Ltd	/s/ Louise Barrett	Louise Barrett	Director	2020-01-31
Iterum Therapeutics plc	/s/ Judith M. Matthews	Judith M. Matthews	Chief Financial Officer	2020-01-31
Iterum Therapeutics US Ltd	/s/ Judith M. Matthews	Judith M. Matthews	Director	2020-01-31
Iterum Therapeutics US Holding Ltd	/s/ Judith M. Matthews	Judith M. Matthews	Director	2020-01-31
Iterum Therapeutics International Ltd	/s/ Louise Barrett	Louise Barrett	Director	2020-01-31